This month, we compared licensing deals with public biotech partners struck by mid-sized European partners to those done by the top 15 Japanese pharmaceutical companies to highlight the differences in dealmaking styles of these highly regional players. We only used deals in which the licensee acquired rights only in its own region, leaving the biotech partner free to license the remainder of the worldwide marketing rights to a multinational.
As the chart below illustrates, it seems Japanese partners are more willing to take a chance on less-proven, earlier-stage technology...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?